Show simple item record

Phase 2a study of the phosphatidylinositol-3-kinase (PI3K) inhibitor copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma

dc.contributor.authorDreyling, MH
dc.contributor.authorMorschhauser, F
dc.contributor.authorBouabdallah, K
dc.contributor.authorCunningham, D
dc.contributor.authorBron, D
dc.contributor.authorLinton, K
dc.contributor.authorAssouline, S
dc.contributor.authorVerhoef, G
dc.contributor.authorThiebtemont, C
dc.contributor.authorVitolo, U
dc.contributor.authorGarcia-Vargas, J
dc.contributor.authorGorbatchevsky, I
dc.contributor.authorNeves, M
dc.contributor.authorGrunet, J
dc.contributor.authorHietneyer, F
dc.contributor.authorChilds, BH
dc.contributor.authorZinzani, PL
dc.date.accessioned2017-09-26T14:22:39Z
dc.date.issued2017-09
dc.identifierhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000405108300776&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4b848928d1c3e5c86d298abb68475f9
dc.identifier.citationONCOLOGY RESEARCH AND TREATMENT, 2017, 40 pp. 310 - 310
dc.identifier.issn2296-5270
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/841
dc.identifier.eissn2296-5262
dc.format.extent310 - 310
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titlePhase 2a study of the phosphatidylinositol-3-kinase (PI3K) inhibitor copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma
dc.typeJournal Article
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2017-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfONCOLOGY RESEARCH AND TREATMENT
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume40
pubs.embargo.termsNot known
icr.researchteamMedicine (RMH Smith Cunningham)en_US
dc.contributor.icrauthorCunningham, David


Files in this item

Thumbnail
Name:
Phase II study of copanlisib.pdf
Size:
9.689Mb
Format:
PDF
Description:
Accepted version
View/Open

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0